AI assistant
Elicio Therapeutics, Inc. — Director's Dealing 2021
Feb 4, 2021
33784_dirs_2021-02-04_a59e61a7-1055-4602-bf09-82ba106b1ec8.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Angion Biomedica Corp. (ANG)
CIK: 0001601485
Period of Report: 2021-02-04
Reporting Person: CURHAN GREGORY S (See Remarks)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $7.78 | 2030-08-30 | Common Stock (56009) | Direct | |
| Stock Option (Right to Buy) | $9.36 | 2024-06-01 | Common Stock (168029) | Direct |
Footnotes
F1: 25% of the total shares subject to the option shall vest immediately on August 31, 2020 and 1/9th of the shares subject to the option will vest monthly thereafter, so that 100% of the shares subject to the option will be fully vested on May 28,2021.
F2: Reflects a 1-to-1.55583 stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement.
F3: One thirty-six (1/36th) of the shares subject to the option will vest on each monthly anniversary measured from June 1, 2021 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the third anniversary of the Vesting Commencement Date.